Title: Survodutide, a glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo‐controlled, dose‐finding, phase 2 trial.
Authors: le Roux, Carel W.; Steen, Oren; Lucas, Kathryn J.; Ekinci, Elif I.; Startseva, Elena; Unseld, Anna; Hussain, Samina Ajaz; Hennige, Anita M.
Abstract: The article discusses a post hoc analysis of a phase 2 clinical trial on survodutide, a dual agonist for glucagon and GLP-1 receptors, in adults with obesity. The study showed significant weight loss and reductions in blood pressure with survodutide treatment compared to placebo. The results suggest that survodutide may help alleviate cardiovascular risk, regardless of hypertension status at baseline. The study was supported by Boehringer Ingelheim, and the authors disclosed potential conflicts of interest related to the research.
Subjects: WEIGHT loss; GLUCAGON-like peptide-1 receptor; ANGIOTENSIN-receptor blockers; GLUCAGON receptors; DIASTOLIC blood pressure; EXENATIDE
Publication: Diabetes, Obesity & Metabolism, 2025, Vol 27, Issue 2, p993
ISSN: 1462-8902
Publication type: Academic Journal
DOI: 10.1111/dom.16052

Survodutide, a glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo‐controlled, dose‐finding, phase 2 trial.

le Roux, Carel W.; Steen, Oren; Lucas, Kathryn J.; Ekinci, Elif I.; Startseva, Elena; Unseld, Anna; Hussain, Samina Ajaz; Hennige, Anita M.